Guey-Shin Wang

Guey-Shin Wang

Auto-generated profile, based on publicly available information

Guey-Shin Wang

Department of Pathology, Baylor College of Medicine, Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2007 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
GWGuey-Shin Wang
Guey-Shin Wang
TCThomas A. Cooper
Thomas A. Cooper

1 October 2007 in Molecular Cell
Verified
Journal Article
Closed access
NKN. Muge Kuyumcu-Martinez
N. Muge Kuyumcu-Martinez
GWGuey-Shin Wang
Guey-Shin Wang
TCThomas A. Cooper
Thomas A. Cooper

1 October 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GWGuey-Shin Wang
Guey-Shin Wang
DKDebra L. Kearney
Debra L. Kearney
MBMariella De Biasi
Mariella De Biasi
GTGeorge Taffet
George Taffet
TCThomas A. Cooper
Thomas A. Cooper
Myotonic dystrophy type 1 (DM1) is caused by a CTG trinucleotide expansion in the 3′ untranslated region (3′ UTR) of DM protein kinase (DMPK). The key feature of DM1 pathogenesis is nuclear accumulation of RNA, which causes aberrant alternative splicing of specific pre-mRNAs by altering the functions of CUG-binding proteins (CUGBPs). Cardiac involvement occurs in more than 80% of individuals with DM1 and is responsible for up to 30% of disease-related deaths. We have generated an inducible and heart-specific DM1 mouse model expressing expanded CUG RNA in the context of DMPK 3′ UTR that recapitulated pathological and molecular features of DM1 including dilated cardiomyopathy, arrhythmias, systolic and diastolic dysfunction, and misregulated alternative splicing. Combined in situ hybridization and immunofluorescent staining for CUGBP1 and CUGBP2, the 2 CUGBP1 and ETR-3 like factor (CELF) proteins expressed in heart, demonstrated elevated protein levels specifically in nuclei containing foci of CUG repeat RNA. A time-course study demonstrated that colocalization of MBNL1 with RNA foci and increased CUGBP1 occurred within hours of induced expression of CUG repeat RNA and coincided with reversion to embryonic splicing patterns. These results indicate that CUGBP1 upregulation is an early and primary response to expression of CUG repeat RNA.

1 April 2004 in Neuron
Verified
Journal Article
Closed access
GWGuey-Shin Wang
Guey-Shin Wang
CHChen-Jei Hong
Chen-Jei Hong
TYTsen-Yann Yen
Tsen-Yann Yen
HHHsin-Yi Huang
Hsin-Yi Huang
YOYvonne Ou
Yvonne Ou
YHYi-Ping Hsueh
Yi-Ping Hsueh

1 December 2009 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GWGuey-Shin Wang
Guey-Shin Wang
MKMuge N. Kuyumcu-Martinez
Muge N. Kuyumcu-Martinez
SSSatyam Sarma
Satyam Sarma
NMNitin Mathur
Nitin Mathur
Xander WehrensXander Wehrens
Xander Wehrens
TCThomas A. Cooper
Thomas A. Cooper
Cardiac complications are a common cause of death in individuals with the inherited multisystemic disease myotonic dystrophy type 1 (DM1). A characteristic molecular feature of DM1 is misregulated alternative splicing due to disrupted functioning of the splicing regulators muscleblind-like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1). CUGBP1 is upregulated in DM1 due to PKC pathway activation and subsequent CUGBP1 protein hyperphosphorylation and stabilization. Here, we blocked PKC activity in a heart-specific DM1 mouse model to determine its pathogenic role in DM1. Animals given PKC inhibitors exhibited substantially increased survival that correlated with reduced phosphorylation and decreased steady-state levels of CUGBP1. Functional studies demonstrated that PKC inhibition ameliorated the cardiac conduction defects and contraction abnormalities found in this mouse model. The inhibitor also reduced misregulation of splicing events regulated by CUGBP1 but not those regulated by MBNL1, suggesting distinct roles for these proteins in DM1 cardiac pathogenesis. The PKC inhibitor did not reduce mortality in transgenic mice with heart-specific CUGBP1 upregulation, indicating that PKC inhibition did not have a general protective effect on PKC-independent CUGBP1 increase. Our results suggest that pharmacological blockade of PKC activity mitigates the DM1 cardiac phenotype and provide strong evidence for a role for the PKC pathway in DM1 pathogenesis.

1 December 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SVSunil K. Verma
Sunil K. Verma
VDVaibhav Deshmukh
Vaibhav Deshmukh
PLPatrick Liu
Patrick Liu
CNCurtis A. Nutter
Curtis A. Nutter
RERosario Espejo
Rosario Espejo
MKMuge Kuyumcu-Martinez
Muge Kuyumcu-Martinez
Diabetic cardiomyopathy is one of the complications of diabetes that eventually leads to heart failure and death. Aberrant activation of PKC signaling contributes to diabetic cardiomyopathy by mechanisms that are poorly understood. Previous reports indicate that PKC is implicated in alternative splicing regulation. Therefore, we wanted to test whether PKC activation in diabetic hearts induces alternative splicing abnormalities. Here, using RNA sequencing we identified a set of 22 alternative splicing events that undergo a developmental switch in splicing, and we confirmed that splicing reverts to an embryonic pattern in adult diabetic hearts. This network of genes has important functions in RNA metabolism and in developmental processes such as differentiation. Importantly, PKC isozymes α/β control alternative splicing of these genes via phosphorylation and up-regulation of the RNA-binding proteins CELF1 and Rbfox2. Using a mutant of CELF1, we show that phosphorylation of CELF1 by PKC is necessary for regulation of splicing events altered in diabetes. In summary, our studies indicate that activation of PKCα/β in diabetic hearts contributes to the genome-wide splicing changes through phosphorylation and up-regulation of CELF1/Rbfox2 proteins. These findings provide a basis for PKC-mediated cardiac pathogenesis under diabetic conditions.